%PDF-1.3
%
3 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 54>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 55>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
12 0 obj
<>stream
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
Arbortext Advanced Print Publisher 9.0.114/W
2016-12-28T07:32:23-08:00
2016-12-28T10:27:51+05:30
application/pdf
MAB-2016-0040-ver9-Ogasawara_3P 304..306
uuid:341b92a7-c06e-4969-accf-b0e70cecd66f
uuid:c5cde8e2-94c3-4fb0-9084-07eeda19ae50
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
20 0 obj
<>stream
/GS1 gs
BT
/F8 1 Tf
8.9663 0 0 8.9663 310.8472 227.8488 Tm
0 0 0 rg
0 Tc
0 Tw
(Acknowledgments)Tj
/F3 1 Tf
9.843 0 0 9.843 320.8251 211.4078 Tm
[(We)-351.2(thank)-352.4(Takuro)-348.8(Nakamura,)-357.6(Noriko)-353.2(Saidoh,)-351(and)-350(Kanae)]TJ
-1.0137 -1.1174 TD
[(Yoshida)-372.5(for)-366.1(their)-369.8(excellent)-377.8(technical)-372.1(assistance.)-375.9(This)-368.4(work)]TJ
0 -1.1116 TD
[(was)-298.9(supported,)-308.2(in)-296.1(part,)-302.8(by)-301.7(the)-304.1(Regional)-300.4(Innovation)-306.2(Strategy)]TJ
T*
[(Support)-376.3(Program)-378.5(from)-374.2(the)-379(Ministry)-378.5(of)-376.5(Education,)-380(Culture,)]TJ
0 -1.1174 TD
[(Sports,)-194.1(Science)-202.4(and)-200.3(Technology)-199(\()-81.7(MEXT\))-199.7(of)-198(Japan)-197.7(\(Y.K.\),)-200.7(by)]TJ
0 -1.1116 TD
[(JSPS)-412.7(KAKENHI)-422.2(Grant)-416.6(Numbers)-419.7(26440019)-412(\()-81.7(M.K.K.\))-420.5(and)]TJ
T*
[(16K10748)-343.8(\(Y.K.\),)-338.9(by)-342(the)-344.4(Platform)-339.5(for)-343.1(Drug)-345.1(Discovery,)-344.7(In-)]TJ
T*
[(formatics,)-431.6(and)-424.9(Structural)-434(Life)-427.3(Science)-432.8(\(PDIS\))-427.5(from)-426(Japan)]TJ
0 -1.1174 TD
[(Agency)-499.4(for)-504.3(Medical)-501.9(Research)-503.8(and)-499.8(Development,)-505.2(AMED)]TJ
0 -1.1116 TD
[(\(Y.K.\),)-218(by)-221.1(Project)-223.2(for)-222.1(utilizing)-219.1(glycans)-223.1(in)-221.2(the)-223.5(development)-224.5(of)]TJ
T*
[(innovative)-255.6(drug)-252(discovery)-254(technologies)-253.1(from)-253.2(AMED)-255.9(\(Y.K.\),)]TJ
0 -1.1174 TD
[(and)-257.9(by)-255.6(the)-258(Basic)-262.2(Science)-260(and)-263.7(Platform)-258.9(Technology)-262.3(Program)]TJ
0 -1.1116 TD
[(for)-187.5(Innovative)-197.9(Biological)-193.5(Medicine)-192(from)-189.9(AMED)-192.6(\(Y.K.\).)-194.9(This)]TJ
T*
[(work)-195.3(was)-201(performed,)-201.1(in)-192.4(part,)-199.2(under)-196.7(the)-200.4(Cooperative)-201.2(Research)]TJ
0 -1.1174 TD
[(Program)-251.8(of)-249.8(Institute)-253.3(for)-250.9(Protein)-250.8(Research,)-253.9(Osaka)-256.2(University,)]TJ
ET
q
206.942 0 0 518.116 75.968 214.129 cm
/Im1 Do
Q
BT
/F4 1 Tf
9.845 0 0 9.845 59.7543 197.348 Tm
[(FIG.)-711(1.)]TJ
/F3 1 Tf
4.4917 0 TD
[(Immunohistochemical)-712.8(analysis)-707.1(against)-712(canine)]TJ
-4.4917 -1.0077 TD
[(melanoma)-468.9(using)-459.9(PMab-38.)-461.3(Canine)-464.4(melanomas)-463.9(\(10)-463.7(cases\))]TJ
0 -1.0135 TD
[(were)-542.7(obtained)-540.4(from)-534.9(North)-535.7(Lab)-540.9(\(Hokkaido,)-538.5(Japan\).)-535.5(Four)]TJ
T*
[(micrometers)-276(thick)-265.6(histologic)-270.7(sections)-269.4(were)-266.3(deparafnized)-272.1(in)]TJ
0 -1.0077 TD
[(xylene,)-276.7(rehydrated,)-276.1(and)-274.8(autoclaved)-274.1(in)-278.6(citrate)-275.9(buffer)-272(\(pH)-274.4(6.0;)]TJ
0 -1.0135 TD
[(Dako,)-447(Glostrup,)-449.9(Denmark\))-449.9(for)-446.4(20)-445.4(minutes.)-450.5(Sections)-447.9(were)]TJ
T*
[(incubated)-577.1(with)-575.2(10)]TJ
/F6 1 Tf
8.0044 0 TD
(m)Tj
/F3 1 Tf
.5528 0 TD
[(g/mL)-570.8(of)-577.8(PMab-38)-573.1(overnight)-574.8(at)-579.2(4)]TJ
/F7 1 Tf
14.667 0 TD
()Tj
/F3 1 Tf
.3973 0 TD
(C)Tj
-23.6215 -1.0135 TD
[(followed)-459.4(by)-451.1(treatment)-457.5(with)-454.3(Envision)]TJ
/F7 1 Tf
15.5193 0 TD
(+)Tj
/F3 1 Tf
1.0077 0 TD
[(kit)-452.5(for)-452.1(30)-451.1(minutes)]TJ
-16.527 -1.0077 TD
[(\(Dako\).)-258.9(As)-261.8(a)-255.5(control,)-259.4(blocking)-257.1(buffer)-260.5(was)-258.2(used)-258.3(in)-255.5(this)-257.5(study.)]TJ
0 -1.0135 TD
[(Color)-656.8(was)-649.7(developed)-657.5(using)-649.9(3,3-diaminobenzidine)-656.4(tetra-)]TJ
T*
[(hydrochloride)-251.7(\(Dako\))-249.8(for)-250.6(2)-248.6(minutes,)-248.9(after)-249.3(which)-254.7(the)-246.2(sections)]TJ
T*
[(were)-358.4(counterstained)-352.9(with)-356.4(hematoxylin)-354.7(\(Wako)-353.8(Pure)-350.5(Chemi-)]TJ
0 -1.0077 TD
[(cal)-402.8(Industries)-402.7(Ltd.,)-402.6(Osaka,)-397.1(Japan\).)-403.1(H&E)-403.5(staining)-401(was)-402.1(also)]TJ
0 -1.0135 TD
[(performed.)-355.5(Scale)-348.2(bar:)-350.8(100)]TJ
/F6 1 Tf
10.8779 0 TD
(m)Tj
/F3 1 Tf
.5528 0 TD
[(m.)-351(mAb,)-348.1(monoclonal)-347.7(antibody;)]TJ
-11.4307 -1.0135 TD
[(PDPN,)-336.9(podoplanin.)]TJ
ET
q
238.023 0 0 354.047 311.414 378.198 cm
/Im2 Do
Q
BT
/F4 1 Tf
9.845 0 0 9.845 310.8472 361.4172 Tm
[(FIG.)-423.1(2.)]TJ
/F3 1 Tf
4.198 0 TD
[(PMab-38)-342.7(reacted)-340(with)-339.1(PDPN)-339.2(of)-336(melanoma)-342.2(cells,)]TJ
-4.198 -1.0135 TD
[(cancer-associated)-158.6(broblasts,)-152.5(and)-153.9(lymphatic)-151.1(endothelial)-159.1(cells.)]TJ
0 -1.0077 TD
[(Sections)-229.1(of)-232.3(melanomas)]TJ
/F4 1 Tf
9.4901 0 TD
(\(A,)Tj
/F3 1 Tf
1.5375 0 TD
[(case)-231.9(7;)]TJ
/F4 1 Tf
2.9714 0 TD
(B,)Tj
/F3 1 Tf
1.146 0 TD
[(case)-231.9(9;)]TJ
/F4 1 Tf
2.9714 0 TD
(C,)Tj
/F3 1 Tf
1.1978 0 TD
[(case)-231.9(2)]TJ
/F4 1 Tf
2.4589 0 TD
(\))Tj
/F3 1 Tf
.5643 0 TD
(were)Tj
-22.3374 -1.0135 TD
[(incubated)-335.2(with)-333.4(10)]TJ
/F6 1 Tf
7.5149 0 TD
(m)Tj
/F3 1 Tf
.5528 0 TD
[(g/mL)-334.7(of)-330.2(PMab-38)-337(overnight)-332.9(at)-331.6(4)]TJ
/F7 1 Tf
13.452 0 TD
()Tj
/F3 1 Tf
.3801 0 TD
-.0162 Tc
[(C)-334.9(fol-)]TJ
-21.8997 -1.0135 TD
0 Tc
[(l)16.1(o)16.3(w)15.5(e)0(d)-227.7(b)0(y)-226.6(t)0(r)26.6(e)15.1(a)15.1(t)0(m)25.5(e)15.1(n)16.3(t)-243(w)15.5(i)16.1(th)-226.7(En)25.6(v)16.3(i)16.1(si)26.8(o)16.3(n)]TJ
/F7 1 Tf
13.1986 0 TD
(+)Tj
/F3 1 Tf
.7947 0 TD
[(k)16.3(i)0(t)-226.9(f)0(o)26.8(r)-242.9(3)16.3(0)-242.8(m)15.1(i)16.1(n)16.3(u)0(t)26.6(e)15.1(s)-242.7(\(Dako\).)]TJ
-13.9933 -1.0135 TD
[(As)-233(a)-232.5(control,)-230.6(blocking)-234(buffer)-237.5(was)-235.1(used.)-232.9(Color)-230.7(was)-235.1(developed)]TJ
0 -1.0077 TD
[(using)-281.4(3,3-diaminobenzidine)-293.6(tetrahydrochloride)-288.1(\(Dako\))-284.3(for)-285.2(2)]TJ
0 -1.0135 TD
[(minutes,)-364.1(after)-358.7(which)-364.1(the)-361.4(sections)-367.3(were)-364.2(counterstained)-364.4(with)]TJ
T*
[(hematoxylin)-510.2(\(Wako\).)-513.6(H&E)-512.9(staining)-516.2(was)-511.5(also)-517.7(performed.)]TJ
T*
[(Scale)-238.8(bar:)-241.4(100)]TJ
/F6 1 Tf
5.8852 0 TD
(m)Tj
/F3 1 Tf
.5471 0 TD
(m.)Tj
/F4 1 Tf
1.2726 0 TD
(\(A\))Tj
/F3 1 Tf
1.6239 0 TD
[(staining)-239.8(of)-243.8(melanoma)-238.5(cells)-243.6(by)-238.1(PMab-)]TJ
-9.3288 -1.0077 TD
(38,)Tj
/F4 1 Tf
1.4569 0 TD
(\(B\))Tj
/F3 1 Tf
1.549 0 TD
[(staining)-211(of)-209.3(cancer-associated)-222(broblasts)-212.5(by)-209.3(PMab-38,)]TJ
-3.006 -1.0135 TD
(and)Tj
/F4 1 Tf
1.6988 0 TD
(\(C\))Tj
/F3 1 Tf
1.6354 0 TD
[(staining)-251.3(of)-249.6(lymphatic)-249(endothelial)-257(cells)-249.3(by)-249.6(PMab-38.)]TJ
/F8 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(CANINE)-341.5(PDPN)-330.2(IN)-335.1(MELANOMA)]TJ
53.0113 0 TD
(305)Tj
ET
endstream
endobj
23 0 obj
<>stream
Adobe d
7
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz m !1AQa"q2#BRbr3$4CS%cs5DT
&6E'dtU7()euFVfvGWgw8HXhx9IYiy*:JZjz ? ?_Knj.fےv4
g)ɕf,1Tm;WH4+S=ZPzI
c2(A|@rM/zi|{yٳsy(1ZkP`g $/?5o[;+
Jkf>[ѷ@e
̧`lzeg-~ͷ_S8 'M?e!h>#C]1Gjk| 5BU yAT\f_qƑYwqi:f&#n
GM0Jd_wz#|.%˂ܠCJ$r
8
dk,\yN5
vLBTȄw&x=WKO7/2j7(,hկ Gr\2BFt"!Ql֥vU4;]!B1KS}]ZI"q<G;ƗrL?YOfJڵ1OB+O9C}1B3/kk\"{'*FԒT_o̞rmzdGq#lvhg&(oO_n|ݥZ]jWG,A ^,Eh